Cargando…
Dorzagliatin, a Dual-Acting Glucokinase Activator, Increases Insulin Secretion and Glucose Sensitivity in Glucokinase Maturity-Onset Diabetes of the Young and Recent-Onset Type 2 Diabetes
Glucokinase (GK, gene symbol GCK) maturity-onset diabetes of the young (MODY) is caused by heterozygous inactivating mutations in GK and impaired glucose sensing. We investigated effects of dorzagliatin, a novel allosteric GK activator, on insulin secretion rates (ISRs) and β-cell glucose sensitivit...
Autores principales: | Chow, Elaine, Wang, Ke, Lim, Cadmon K.P., Tsoi, Sandra T.F., Fan, Baoqi, Poon, Emily, Luk, Andrea O.Y., Ma, Ronald C.W., Ferrannini, Ele, Mari, Andrea, Chen, Li, Chan, Juliana C.N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871194/ https://www.ncbi.nlm.nih.gov/pubmed/36342518 http://dx.doi.org/10.2337/db22-0708 |
Ejemplares similares
-
Decreased expression of hepatic glucokinase in type 2 diabetes
por: Haeusler, Rebecca A., et al.
Publicado: (2014) -
Phenotypic and Genetic Heterogeneity in a Thai Glucokinase MODY Family Reveals the Complexity of Young-Onset Diabetes
por: Thewjitcharoen, Yotsapon, et al.
Publicado: (2021) -
Effect of renal impairment on the pharmacokinetics and safety of dorzagliatin, a novel dual‐acting glucokinase activator
por: Miao, Jia, et al.
Publicado: (2021) -
Pregnancy outcome of Japanese patients with glucokinase–maturity‐onset diabetes of the young
por: Hosokawa, Yuki, et al.
Publicado: (2019) -
Phenotype Heterogeneity in Glucokinase–Maturity-Onset Diabetes of the Young (GCK-MODY) Patients
por: Wędrychowicz, Anna, et al.
Publicado: (2017)